To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants

Phase 1 Completed 36 enrolled SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to determine the effect of carbamazepine on the blood levels of mirdametinib and how long it takes the body to eliminate mirdametinib when both drugs are administered orally in healthy participants. The study may last up to approximately 64 days for each participant.

Timeline

Start: 2025-12-15
Primary completion: 2026-02-27
Completion: 2026-02-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carbamazepine	Small molecule	300 mg	Oral
Subject	Mirdametinib	Small molecule	6 mg	Oral

Indications

No indication recorded.